Histogen Inc. (HSTO)
OTCMKTS: HSTO · Delayed Price · USD
0.150
-0.050 (-25.00%)
May 3, 2024, 3:07 PM EDT - Market closed
Histogen Revenue
Histogen had revenue of $19.00K in the twelve months ending September 30, 2023, down -99.50% year-over-year. Revenue in the quarter ending September 30, 2023 was $5.00K. In the year 2022, Histogen had annual revenue of $3.77M with 310.12% growth.
Revenue (ttm)
$19.00K
Revenue Growth
-99.50%
P/S Ratio
33.72
Revenue / Employee
$2,714
Employees
7
Market Cap
640.76K USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 3.77M | 2.85M | 310.12% |
Dec 31, 2021 | 919.00K | -1.14M | -55.37% |
Dec 31, 2020 | 2.06M | -9.25M | -81.79% |
Dec 31, 2019 | 11.30M | -22.28M | -66.34% |
Dec 31, 2018 | 33.59M | -1.79M | -5.06% |
Dec 31, 2017 | 35.38M | 34.58M | 4,327.36% |
Dec 31, 2016 | 799.05K | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 81.80B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.33B |
HSTO News
- 15 days ago - Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering - GlobeNewsWire
- 5 months ago - Histogen Announces Second Adjournment of Special Meeting of Stockholders - GlobeNewsWire
- 5 months ago - Histogen Announces Adjournment of Special Meeting of Stockholders - GlobeNewsWire
- 8 months ago - Histogen Announces Board Approval of Complete Liquidation and Dissolution - GlobeNewsWire
- 9 months ago - Conatus Global Opens the Door for Lucrative Funding from Top Tier Venture Capitalists - Newsfile Corp
- 10 months ago - Histogen to Explore Strategic Alternatives - GlobeNewsWire
- 1 year ago - Histogen Reports First Quarter 2023 Results and Provides Business Update - GlobeNewsWire
- 1 year ago - Histogen Announces Online Publication in the Journal of Investigative Dermatology - GlobeNewsWire